“The computational medicine and drug discovery software market encompasses the use of pharmacy, chemistry, biotechnology and software knowledge for drug discovery and development. This is accompanied by development of algorithms and simulation of various models to study the pharmacokinetics and pharmacodynamics of a particular drug.
The global market for computational medicine and drug discovery software is valued at $X billion in 2014 and is projected to grow with a healthy double digit CAGR of XX% through 2020. Recent growth in disease modeling, drug designing and development by leveraging various bioinformatics tools will lead to the market growth during the period under study (2014-2020).
As of 2014, the application of computational medicine in simulation of cells is estimated to grow at the fastest pace, due to the increasing research activities on sequencing of proteins to design and develop customized medicines suited to an individual’s needs. Drug discovery, development and disease modeling applications occupy the highest market share owing to the widespread drug development approaches adopted by several major pharmaceutical companies.
The North America, led by the U.S. accounted for the largest market share in the global market for computational medicine and drug discovery software, occupying over 55% of the revenue in 2014. The huge market size can be credited to the increasing investments in R&D activities pertaining to drug discovery and development and disease modelling.”
“1. Global Computational Medicine and Drug Discovery Software Market Overview
2. Executive Summary
3. Global Computational Medicine and Drug Discovery Software Market Landscape
3.1. Market share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End-User Profiling
3.2.3. Patent Analysis
3.2.4. Top 5 Financial Analysis
4. Global Computational Medicine and Drug Discovery Software – Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Global Computational Medicine and Drug Discovery Software Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunity Analysis
5.4. Product Life Cycle Analysis
5.5. Suppliers & Distributors
6. Global Computational Medicine and Drug Discovery Software Market – By Tools
6.1. Introduction
6.2. Databases
6.3. Software
6.4. Others
7. Global Computational Medicine and Drug Discovery Software Market – By Application
7.1. Introduction
7.2. Computational Physiological Medicine
7.3. Drug Discovery and Development
7.4. Medical Imaging
7.5. Disease Modelling
7.6. Predictive Analysis of Drug Targets
7.7. Cellular Simulation
7.8. Simulation Software
7.9. Others
8. Global Computational Medicine and Drug Discovery Software Market – By Geography
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. U.K.
8.3.2. Germany
8.3.3. Netherlands
8.3.4. Norway
8.3.5. Italy
8.3.6. Others
8.4. APAC
8.4.1. China
8.4.2. Japan
8.4.3. Korea
8.4.4. Australia
8.4.5. Others
8.5. RoW
9. Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, Partnerships & JVs
10. Investment Opportunities
11. Company Profiles
11.1. Aurora Fine Chemicals LLC
11.2. Biognos AB
11.3. Certara, L.P.
11.4. Chemical Computing Group Inc.
11.5. CLC bio
11.6. Collaborative Drug Discovery, Inc.
11.7. Compugen Ltd.
11.8. Crown Bioscience Inc.
11.9. Dassault Systemes, BIOVIA Corp.
11.10. Domainex Ltd
11.11. Entelos, Inc.
11.12. Genedata AG
11.13. Leadscope, Inc.
11.14. Nimbus Therapeutics
11.15. Prosarix Ltd
11.16. Quant Med LLC
11.17. Quantum Pharmaceuticals
11.18. Rhenovia Pharma Limited
11.19. Simulations Plus, Inc.
11.20. Schrödinger, LLC
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
“”*Financials would be provided on a best efforts basis for private companies””
12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Bibliography
12.5. Compilation of Expert Insights
12.6. Disclaimer”
“11.1. Aurora Fine Chemicals LLC
11.2. Biognos AB
11.3. Certara, L.P.
11.4. Chemical Computing Group Inc.
11.5. CLC bio
11.6. Collaborative Drug Discovery, Inc.
11.7. Compugen Ltd.
11.8. Crown Bioscience Inc.
11.9. Dassault Systemes, BIOVIA Corp.
11.10. Domainex Ltd
11.11. Entelos, Inc.
11.12. Genedata AG
11.13. Leadscope, Inc.
11.14. Nimbus Therapeutics
11.15. Prosarix Ltd
11.16. Quant Med LLC
11.17. Quantum Pharmaceuticals
11.18. Rhenovia Pharma Limited
11.19. Simulations Plus, Inc.
11.20. Schrödinger, LLC”
